Evaluation of effectiveness of orlistat in complexed obesity treatment in teenagers with metabolic syndrome
https://doi.org/10.14341/2071-8713-5302
Abstract
An open, comparative, randomized study of orlistat in the combined treatment of obesity in adolescents with metabolic syndrome
(IIIb phase) was held. Objective: to evaluate the efficacy and safety of the orlistat in adolescents 12-17 years with high risk of cardiovascular
disease and type 2 diabetes. The study included 60 adolescents with obesity and metabolic syndrome. The main group (n=30)
followed a hypocaloric diet and aerobic exercises and took orlistat 120 mg 3 times daily with meals, the control (n=30) group was only
on the non-drug therapy. During the study the anthropometric parameters, lipid, carbohydrate metabolism, blood pressure were evaluated.
All comparisons were performed as two-way, with the critical level of significance ≤ 0,05. Results: After 6 months therapy of orlistat
68% of adolescents achieved clinically meaningful weight loss, that led to the improvement of metabolic parameters. On therapy body
fat decreased by -6600.00 g [-7912.00, -2350.00] in the control group, respectively -2235.50 g [-4700, 00; 667.00] (p=0.011). Orlistat
was well tolerated by patients. Most adverse events (9 of 13 in the intervention group) were mild and can be attributed to the expected
adverse reactions. Conclusion: The study demonstrated clinically significant efficacy (compared with the control group), combined with
good safety records of its use in adolescents 12-17 years old with obesity and metabolic disorders.
(IIIb phase) was held. Objective: to evaluate the efficacy and safety of the orlistat in adolescents 12-17 years with high risk of cardiovascular
disease and type 2 diabetes. The study included 60 adolescents with obesity and metabolic syndrome. The main group (n=30)
followed a hypocaloric diet and aerobic exercises and took orlistat 120 mg 3 times daily with meals, the control (n=30) group was only
on the non-drug therapy. During the study the anthropometric parameters, lipid, carbohydrate metabolism, blood pressure were evaluated.
All comparisons were performed as two-way, with the critical level of significance ≤ 0,05. Results: After 6 months therapy of orlistat
68% of adolescents achieved clinically meaningful weight loss, that led to the improvement of metabolic parameters. On therapy body
fat decreased by -6600.00 g [-7912.00, -2350.00] in the control group, respectively -2235.50 g [-4700, 00; 667.00] (p=0.011). Orlistat
was well tolerated by patients. Most adverse events (9 of 13 in the intervention group) were mild and can be attributed to the expected
adverse reactions. Conclusion: The study demonstrated clinically significant efficacy (compared with the control group), combined with
good safety records of its use in adolescents 12-17 years old with obesity and metabolic disorders.
References
1. Дедов И.И., Мельниченко Г.А., Бутрова С.А., Савельева Л.В. и соавт. Ожирение у подростков России // Ожирение и метаболизм. - 2006. - № 4. - С. 30-34.
2. Дедов И. И., Семичева Т.В., Петеркова В.А. Половое развитие детей: норма и патология. - М.: Колор Ит Студио. - 2002.
3. Петеркова В.А., Ремизов О.В. Ожирение в детском возрасте. В кн.: Ожирение: этиология, патогенез, клинические аспекты / Под ред. И.И. Дедова, Г.А. Мельниченко. - М.: Медицинское информационное агентство, 2004. - С. 312-329.
4. Старкова Н.Т., Бирюкова Е.В. Ожирение у подростков. В кн.: Ожирение: этиоло- гия, патогенез, клинические аспекты / Под ред. И.И. Дедова, Г.А. Мельниченко. М.: Медицинское информационное агентство. - 2004. - С. 332-349.
5. Freedman D.S., Dietz W.H., Srinivasan S.R., Berenson G.S. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study // Pediatrics. - 1999. - № 103. - Р. 1175-1182.
6. Daniels S.R., Arnett D.K., Eckel R.H., Gidding S.S., Hayman L.L., Kumanyika S., Robinson T.N., Scott B.J., St. Jeor S., Williams C.L. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment // Circulation. - 2005. - № 111. - Р. 1999-2012.
7. Dietz W.H., Robinson T.N. Overweight children and adolescents // N Engl J Med. - 2005. - № 352. - Р. 2100-2109.
8. Chanoine et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial // JAMA. - 2005. - № 293(23). - Р. 2873-83.
9. Cole T., Bellizzi M.C., Flegal K.M., and Dietz W.H. Establishing a standard definition for child overweight and obesity worldwide: international survey // BMJ. - 2000. - № 320. - Р. 1240-1243.
10. McDuffie J.R. et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African-American and Caucasian adolescents with obesity-related comorbid conditions // J Pediatr Endocrinol Metabol. - 2004. - № 17. - Р. 307-19.
11. Kamath C.C., Vickers K.S., Ehrlich A., McGovern L., Johnson J., Singhal V., Paulo R., Hettinger A., Erwin P.J., Montori V.M. Clinical review: behavioral interventions to prevent childhood obesity: a systematic review and metaanalyses of randomized trials // J Clin Endocrinol Metab. - 2008. - № 93(12). - Р. 4606-15.
12. Kavey R.E., Daniels S.R., Lauer R.M., Atkins D.L., Hayman L.L., Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood // Circulation. - 2003. - № 107. - Р. 1562-1566.
13. Norgren S. et al. Orlistat treatment in obeseprepubertal children: a pilot study // Acta Paediatr. - 2003. - № 92(6). - Р. 666-70.
14. Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion // JCEM. - 2008. -№ 93(12). - Р. 4576-4599.
15. Srinivasan S et al. Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood. The Bogalusa Heart Study // Diabetes. - 2002. - № 51. - Р. 204-9.
16. www.bma.org.uk/ap.nsf/content/childhoodobesity.
17. www.iaso.org.
18. www.who.int.
Review
For citations:
, , , Evaluation of effectiveness of orlistat in complexed obesity treatment in teenagers with metabolic syndrome. Obesity and metabolism. 2011;8(4):36-42. (In Russ.) https://doi.org/10.14341/2071-8713-5302
Views:
476
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
